Co-developed with Mylan
Mylan and Biocon announced that the European Medicines Agency has accepted for review Mylan's Marketing Authorization Application for the their jointly developed biosimilar, Pegfilgrastim, which is used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy.Powered by Capital Market - Live News
